New PET tracer aims to light up tau tangles in the brain
NCT ID NCT06932809
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a new radioactive tracer called 18F-JSS20-183A to see if it can safely and accurately detect abnormal tau protein in the brain during PET scans. Researchers will study 90 adults aged 40-85 with tauopathies (like PSP, Alzheimer's, or Parkinson's) and healthy volunteers. The goal is to improve diagnosis of these brain diseases by measuring where the tracer goes and how long it stays.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 18F-JSS20-183A (a radioactive tracer for PET scans)
- What this could lead to
- If successful, this could lead to a more accurate way to diagnose tau-related brain diseases like PSP and Alzheimer's using a simple PET scan.
- What could go wrong
- This is a very early, small study focused on safety and imaging, not treatment. The tracer may not clearly distinguish between diseases or may have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2025
- Expected to finish
-
Apr 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
40 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients in all cohorts will be male or female adults from 40 to 85 years of age. 2. Participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures or Participants who are deemed unable to provide informed consent must have a designated study partner present for consent and to accompany them to study visits. Investigators will ask disease cohort participants to agree to brain donation, but this choice is not mandatory for participation in this study. Diagnosis-specific inclusion criteria: Clinical diagnoses will be determined by consensus committee (except AD and HC cohorts) for diagnostic agreement using video exams of each participant that are stored at WashU in a secured video repository with view-only access exclusively by secured virtual private network (VPN) connection. Video exam and screening assessments for PSP, CBS, MSA, PD, and FTLD may not be required to be repeated if they have been done within 6 months of enrollment, unless requested at the discretion of an investigator to document changes in clinical progression. A consensus committee will not be required to be repeated for participants who have already had a consensus committee diagnosis documented. Exclusion Criteria: 1. Females who are pregnant or breast feeding will be excluded, a urine pregnancy test will be performed in women of child-bearing potential prior to injection of 18F-JSS20-183A 11C-PiB or 18F-Florbetaben 2. Forms of parkinsonism other than PSP-RS, and PD as defined above 3. History of significant or ongoing alcohol abuse or substance abuse or dependence based on medical record review or self-reported 4. Contraindications or inability to tolerate imaging, arterial line or IV placement or blood draw procedures in the opinion of an investigator or treating physician 5. Contraindication to MRI, such as non-compatible implanted medical device 6. Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician or investigator to be a condition that could compromise participant safety or successful participation in the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Corticobasal syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of California
RECRUITINGSan Francisco, California, 94143, United States
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new PET tracer reveal hidden tau in the brain?
- AI hunts for early clues to Parkinson's and Alzheimer's progression
- Can 30,000 patients reveal Parkinson's hidden patterns?
- High-Resolution brain scans aim to unmask Tau's role in Parkinson's
- PET scans reveal hidden brain inflammation in rare movement disorder
- Scientists map Brain's 'Roads' to predict dementia spread